Novel Agents for Treatment of High-risk COVID-19 Positive Patients
Status:
Recruiting
Trial end date:
2022-05-01
Target enrollment:
Participant gender:
Summary
This is a multi-arm, phase II trial for rapid efficacy and toxicity assessment of multiple
therapies immediately after COVID19 positive testing in high-risk individuals. Therapies
include stand-alone or combination treatment with hydroxychloroquine, azithromycin,
ivermectin, or camostat mesilate, artemesia annua. The hypothesis of this study is that the
addition of agents that inhibit viral entry or replication of SARS-CoV-2 virus replication in
will be devoid of additional moderate to severe toxicities, will prevent clinical
deterioration, and will improve viral clearance in high risk individuals.